

Supplementary Table S1 Summary of studies on follow ups of thrombotic events in isolated OAPS.

Year	Author	Sample size (cases)	Incidence of thrombotic events	Follow-up	Thrombotic events	Risk factors for thrombosis in OAPS patients
2001	Erkan et al. ⁶	65	32.3% (21/65)	8.1 years	Venous (n=7) Stroke (n=5) TIA (n=7) Arterial (n=1) CAPS (n=1)	-
2011	Lefèvre et al. ²	32	3.3/100 patient-years	50 months	TIA, DVT and PE (n=1) DVT and PE (n=2) PE (n=1)	-
2012	Gris et al. ⁷	517	Annual rates were 0.66% for PE, 1.82% for DVT, 0.68% for SVT, and 0.34% for stroke	Nearly 9.5 years	PE (n=20) DVT (n=68) SVT (n=21) TIA or stroke (n=15)	LA
2012	Martinez-Zamora et al. ⁸	57	2.56/100 patient-years 12-year cumulative incidence rate: 19.3%	7.3 years	Stroke (n=6) DVT (n=2) PE (n=2)	Presence of aPLs
2015	Alijotas-Reig et al. ⁹	247	9.8% (16/164)	3 years	Venous (n=13) Arterial (n=3)	-

2017	Drozidnsky et al. ¹⁰	115	10.4% (12/115)	10.9 years	TIA (n=6) Stroke (n=3) PE (n=1) Ovarian vein (n=1) DVT (n=1)	-
2018	Rottenstreich et al. ¹¹	62	30.6% (19/62)	61 months	DVT (n=6) DVT with PE (n=6) Stroke (n=5) TIA (n=2) PE (n=1)	-
2019	de Jesús et al. ⁴	99	4.9/100 patient years	7.6 years	Venous (n=25) Arterial (n=17) Both (n=5)	Younger age, additional cardiovascular risk factors, SVT, heart valve disease, multiple aPL positivity, and higher aGAPSS
2019	Udry et al. ¹²	79	7.6% (6/79)	5 years	DVT (n=6)	-
2019	Alijotas-Reig et al. ¹³	1000	3.1% (31/1000)	7 years	Venous (n=25) Arterial (n=36)	-
2021	Tonello et al. ¹⁴	94	0.49/100 patient years	8.7 years	Venous (n=1) Arterial (n=3)	Presence of LA
2021	Jiang et al. ¹⁵	44	2.27% (1/44)	61 months	Venous (n=1)	-
2022	Niznik et al. ¹⁶	67	35.8% (24/67)	>10 years	Venous (n=13) Arterial (n=6) Both (n=6)	Heart valve disease and ANA positivity

OAPS, obstetric antiphospholipid syndrome; TIA, transient ischemic attack; CAPS, catastrophic antiphospholipid syndrome; PE, pulmonary embolism; DVT, deep vein thrombosis; SVT, superficial vein thrombosis; LA, lupus anticoagulant; aPLs, antiphospholipid antibodies; aGAPSS, adjusted global antiphospholipid syndrome score; ANA, antinuclear antibody.